Roche’s Columvi combo doubles survival in hard-to-treat lymphoma
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
Expands bioprocessing footprint across Asia
The study met its primary endpoint and all 11 secondary efficacy endpoints
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
HYMPAVZI’s safety profile was generally favorable
76 of 180 long COVID-associated genes also linked to ME
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Subscribe To Our Newsletter & Stay Updated